GSK plc (NYSE:GSK) Position Increased by Thrive Wealth Management LLC

Thrive Wealth Management LLC increased its position in GSK plc (NYSE:GSK) by 23.3% in the first quarter, HoldingsChannel reports. The firm owned 11,642 shares of the pharmaceutical company’s stock after acquiring an additional 2,198 shares during the period. Thrive Wealth Management LLC’s holdings in GSK were worth $499,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GSK. LPL Financial LLC boosted its stake in GSK by 11.3% in the 3rd quarter. LPL Financial LLC now owns 579,545 shares of the pharmaceutical company’s stock worth $21,009,000 after purchasing an additional 58,790 shares during the period. Mariner LLC lifted its position in GSK by 12.1% in the 3rd quarter. Mariner LLC now owns 103,193 shares of the pharmaceutical company’s stock worth $3,741,000 after buying an additional 11,169 shares in the last quarter. Federated Hermes Inc. lifted its position in GSK by 64.1% in the 3rd quarter. Federated Hermes Inc. now owns 219,387 shares of the pharmaceutical company’s stock worth $7,953,000 after buying an additional 85,699 shares in the last quarter. Northern Trust Corp lifted its position in GSK by 11.8% in the 3rd quarter. Northern Trust Corp now owns 1,648,878 shares of the pharmaceutical company’s stock worth $59,772,000 after buying an additional 173,748 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC lifted its position in GSK by 16.8% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 5,583 shares of the pharmaceutical company’s stock worth $202,000 after buying an additional 803 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Up 0.3 %

Shares of GSK stock traded up $0.10 on Friday, hitting $38.74. The company’s stock had a trading volume of 197,978 shares, compared to its average volume of 3,600,457. The stock has a market capitalization of $80.29 billion, a price-to-earnings ratio of 14.01, a P/E/G ratio of 1.17 and a beta of 0.66. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The firm’s fifty day moving average price is $42.55 and its 200-day moving average price is $41.17.

GSK (NYSE:GSK) last released its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The firm had revenue of $9.34 billion during the quarter, compared to analyst estimates of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. Research analysts anticipate that GSK plc will post 4.11 EPS for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a yield of 3.88%. GSK’s payout ratio is currently 53.26%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on GSK. The Goldman Sachs Group began coverage on shares of GSK in a research report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price for the company. Citigroup upgraded shares of GSK to a “strong-buy” rating in a research report on Monday. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Finally, Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $47.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.